CLINICAL SIGNIFICANCE OF COMBINING BCR-ABL1 TRANSCRIPT LEVELS AT 3 AND 6 MONTHS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FRONTLINE SECOND-GENERATION TYROSINE KINASE INHIBITORS

被引：0

作者：

Lee, S. E. ^{[1
,2
]}

Choi, S. Y. ^{[2
]}

Kim, S. H. ^{[2
]}

Oh, Y. J. ^{[2
]}

Chae, M. J. ^{[2
]}

Song, H. Y. ^{[2
]}

Yoo, H. L. ^{[2
]}

Lee, M. Y. ^{[2
]}

Jang, E. J. ^{[2
]}

Jeong, K. H. ^{[2
]}

Lee, J. S. ^{[2
]}

Kim, D. W. ^{[1
,2
]}

机构：

[1] Catholic Univ Korea, Seoul St Marys Hosp, Dept Hematol, Seoul, South Korea

[2] Catholic Univ Korea, Canc Res Inst, Seoul, South Korea

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PB1546

引用

页码：599 / 599

页数：1

共 50 条

[21] PREDICTIVE FACTORS FOR OUTCOME TO NOVEL BCR-ABL1 TYROSINE KINASE INHIBITORS IN IMATINIB FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Lee, S. E.
Choi, S. Y.
Kim, S. H.
Oh, Y. J.
Chae, M. J.
Song, H. Y.
Yoo, H. L.
Lee, M. Y.
Jang, E. J.
Jeong, K. H.
Lee, J. S.
Kim, D. W.
HAEMATOLOGICA, 2014, 99 : 336 - 336
[22] Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
Erbilgin, Yucel
Eskazan, Ahmet Emre
Ng, Ozden Hatirnaz
Salihoglu, Ayse
Elverdi, Tugrul
Firtina, Sinem
Tasar, Orcun
Mercan, Sevcan
Sisko, Sinem
Khodzhaev, Khusan
Ongoren, Seniz
Ar, Muhlis Cem
Baslar, Zafer
Soysal, Teoman
Sayitoglu, Muge
Ozbek, Ugur
LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 200 - 207
[23] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
Swords R.
Alvarado Y.
Cortes J.
Giles F.J.
Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
[24] Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis
Chen, Kangkang
Ruan, Yingying
Tian, Kewei
Xiong, Peisheng
Xia, Nan
Li, Jin
Huang, Wen
Cao, Feiyan
Chen, Qifeng
FRONTIERS IN ONCOLOGY, 2022, 12
[25] Outcome of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience
Lee, Sung-Eun
Choi, Soo Young
Kim, Soo-Hyun
Song, Hye-Young
Yoo, Hea-Lyun
Lee, Mi-Young
Kang, Ki-Hoon
Hwang, Hee-Jeong
Jang, Eun-Jung
Kim, Dong-Wook
BLOOD, 2015, 126 (23)
[26] BCR-ABL1 Transcript of 7.93% at 3 Months Is an Early Predictor for Long-Term Survival to Second-Line Therapy Using Next Generation Tyrosine Kinase Inhibitors in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia
Lee, Sung-Eun
Choi, Soo Young
Oh, Yun Jeong
Kim, Soo-Hyun
Song, Hye-Young
Yoo, Hea-Lyun
Lee, Mi-Young
Chae, Moon-Jung
Kang, Ki-Hoon
Hwang, Hee-Jeong
Jang, Eun-Jung
Kim, Dong-Wook
BLOOD, 2014, 124 (21)
[27] Second generation tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia
le Coutre, P.
Baskaynak, G.
Schwarz, M.
Petereit, C.
Westermann, J.
Dorken, B.
ANNALS OF ONCOLOGY, 2007, 18 : 17 - 17
[28] OUTCOMES OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH 10%≤AND>10% BCR-ABL1 (IS) TRANSCRIPT LEVELS AFTER 3 MONTHS OF GENERIC IMATINIB TREATMENT
Baslar, Z.
Eskazan, A. E.
Ayer, M.
Kantarcioglu, B.
Demirel, N.
Aydin, D.
Aydinli, F.
Yokus, O.
Sadri, S.
Erdogan, I.
Berk, S.
Yalniz, F. F.
Elverdi, T.
Salihoglu, A.
Ar, M. C.
Aydin, S. Ongoren
Aydin, Y.
Tuzuner, N.
Ozbek, U.
Soysal, T.
HAEMATOLOGICA, 2015, 100 : 439 - 440
[29] Impact of BCR-ABL Transcript Subtypes in Achieving Major Molecular Remission in Chronic Phase, Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
Ali, Naveed
Naglak, Mary
Auerbach, Herbert Edward
Berman, Jessica
Pickens, Peter V.
BLOOD, 2017, 130
[30] Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Trivedi, Digisha
Amin, Shahla
Zhu, Ling
Joo, Sam
Kawabata, Hugh
Darkow, Theodore
Hebden, Tony
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →